TAP returns Spectracef rights
TAP returns Spectracef (ceftidoren) rights to Japan-based Meiji Seika Kaisha. The cephalosporin antibiotic was approved Aug. 29, 2001 for treatment of acute exacerbation of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections (1"The Pink Sheet" Sept. 1, 2003, p. 20)...
You may also be interested in...
Bharat Biotech’s COVID-19 vaccine has shown 80.6% efficacy in interim data from Phase III clinical trials, slightly better than the 79.3% reported by Sinopharm and significantly higher than Sinovac’s 50.6% for their vaccines based on similar technology. Supply deals are already on the way, with Brazil having signed up for 200 million doses.
A medicines manufacturing “road map” set out by Australia’s government has the backing of the local off-patent industry.
Boston Scientific has agreed to pay $1.07bn to acquire Lumenis’ surgical laser business from Baring Private Equity Asia. See what Meghan Scanlon, president of Boston Scientific’s urology and pelvic health business, said about it here.